GB201301771D0 - A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depression - Google Patents
A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depressionInfo
- Publication number
- GB201301771D0 GB201301771D0 GBGB1301771.0A GB201301771A GB201301771D0 GB 201301771 D0 GB201301771 D0 GB 201301771D0 GB 201301771 A GB201301771 A GB 201301771A GB 201301771 D0 GB201301771 D0 GB 201301771D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- chronic fatigue
- fibromyalgia
- depression
- formulation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1301771.0A GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
GB1321945.6A GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1301771.0A GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201301771D0 true GB201301771D0 (en) | 2013-03-20 |
GB2510374A GB2510374A (en) | 2014-08-06 |
Family
ID=47988520
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1301771.0A Withdrawn GB2510374A (en) | 2013-01-31 | 2013-01-31 | Formulation comprising N-acetylcarnitine and D-ribose |
GB1321945.6A Expired - Fee Related GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1321945.6A Expired - Fee Related GB2510477B (en) | 2013-01-31 | 2013-12-11 | Formulations for use in the treatment of chronic fatigue and associated conditions, etc |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB2510374A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114208971A (en) * | 2021-11-29 | 2022-03-22 | 中国科学院水生生物研究所 | Application of D-ribose in feed for improving flavor and meat quality of crucian |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017120731A1 (en) * | 2016-01-11 | 2017-07-20 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Methods and compositions for reducing body weight |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
IT1317043B1 (en) * | 2000-06-14 | 2003-05-26 | Sigma Tau Healthscience Spa | FOOD SUPPLEMENT ENHANCING THE ENERGETIC-MUSCULAR METABOLISM, INCLUDING AN ALCANOIL L-CARNITINE AND RIBOSE. |
AU2002359618A1 (en) * | 2001-12-06 | 2003-06-23 | Weller Health, Inc. | Medicinal compositions and therapeutic methods |
US20040241256A1 (en) * | 2002-12-05 | 2004-12-02 | Seymour Ehrenpreis | Medicinal compositions & therapeutic methods |
JP4754484B2 (en) * | 2004-03-18 | 2011-08-24 | 田辺三菱製薬株式会社 | Depressive symptom improving agent |
US20080233245A1 (en) * | 2007-03-19 | 2008-09-25 | Lesley Joan White | Liquid nutrient composition for improving performance |
US8466198B2 (en) * | 2008-09-02 | 2013-06-18 | Bruce Kneller | Compositions comprising creatine salts and methods of use thereof |
TW201201712A (en) * | 2010-01-28 | 2012-01-16 | Max International Llc | Compositions comprising sugar-cysteine products |
US20130059038A1 (en) * | 2011-09-01 | 2013-03-07 | John C. Gilkey | Nutritional composition |
-
2013
- 2013-01-31 GB GB1301771.0A patent/GB2510374A/en not_active Withdrawn
- 2013-12-11 GB GB1321945.6A patent/GB2510477B/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114208971A (en) * | 2021-11-29 | 2022-03-22 | 中国科学院水生生物研究所 | Application of D-ribose in feed for improving flavor and meat quality of crucian |
Also Published As
Publication number | Publication date |
---|---|
GB2510477B (en) | 2017-12-13 |
GB2510477A (en) | 2014-08-06 |
GB201321945D0 (en) | 2014-01-22 |
GB2510374A (en) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1220918A1 (en) | Cytokine derived treatment with reduced vascular leak syndrome | |
GB201409813D0 (en) | Methods, apparatuses and computer programs for adapting content | |
HUE054577T2 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
EP3019082A4 (en) | Determining respiratory parameters | |
IL244427A0 (en) | Systems, devices and methods for anti-tl1a therapy | |
EP2999421A4 (en) | Cyrogenic treatment systems | |
EP3035993A4 (en) | Selecting and delivering treatment agents based on a microbe profile | |
GB201417264D0 (en) | Content mirroring | |
EP3357679A4 (en) | Humidifying device and corrugating machine | |
HUE044207T2 (en) | A modified surface capable of having bacteriostatic and bactericide activity, the method for obtaining it and use thereof | |
GB201401711D0 (en) | Non-uniform constellations | |
GB201408673D0 (en) | Medicaments,uses and methods | |
GB2553840B (en) | Robots, methods, computer programs and computer-readable media | |
EP3022298A4 (en) | Attenuated influenza vaccines and uses thereof | |
EP3007834A4 (en) | Device for, or in, the surface treatment of objects | |
PL3488612T3 (en) | Apparatuses, methods, computer programs and computer-readable media | |
EP2640397A4 (en) | Methods for the treatment of fibromyalgia and chronic fatigue syndrome | |
HK1250626A1 (en) | Combination treatments with seribantumab | |
EP3065726A4 (en) | Creatine analogs and the use thereof | |
HK1258293A1 (en) | Assistance implement for ameliorating sleep apnea syndrome | |
GB201301771D0 (en) | A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depression | |
GB2538877B (en) | Passive NOx adsorber | |
PL2835245T3 (en) | Two component condensate hose | |
AU2013901661A0 (en) | A treatment and diagnosis of chronic fatigue syndrome | |
GB201314141D0 (en) | P9 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |